Peek Under The Hood: SPSM Has 13% Upside

An analysis of the SPDR Portfolio S&P 600 Small Cap ETF (SPSM) reveals an implied analyst target price of $49.93, indicating a 13.26% upside from its current $44.08, derived from the weighted average of 12-month forward analyst targets for its underlying holdings. This suggests potential value in the small-cap segment, with key constituents such as Rogers Corp. (ROG), Encore Capital Group Inc (ECPG), and Myriad Genetics, Inc. (MYGN) exhibiting even higher individual analyst-projected upsides ranging from 36.46% to 39.57%.

Analysis

Based on a weighted average of analyst 12-month forward price targets for its underlying holdings, the SPDR Portfolio S&P 600 Small Cap ETF (SPSM) exhibits an implied upside of 13.26%, with a calculated target price of $49.93 per unit against its recent trading price of $44.08. This suggests a moderately positive sentiment among analysts for the small-cap segment. The potential upside is significantly influenced by specific constituents such as Rogers Corp. (ROG), Encore Capital Group Inc (ECPG), and Myriad Genetics, Inc. (MYGN), which have analyst-projected upsides of 39.57%, 39.06%, and 36.46%, respectively. However, the analysis is inherently speculative, as it relies on aggregated analyst forecasts. The wide disparity between current prices and target prices for these individual stocks necessitates further diligence, as it could signal either a significant valuation opportunity or that analyst targets are overly optimistic and may be subject to future downgrades.

Key Decisions for Investors

• Investors looking for broad exposure to the small-cap sector could consider SPSM, given the aggregate analyst view suggests a 13.26% potential return.
• For those with a higher risk tolerance, conducting deep fundamental analysis on the heavily discounted underlying holdings like ROG, ECPG, and MYGN could unlock alpha if the bullish analyst targets are validated.
• It is crucial to assess the risk of potential target price downgrades, as the significant gap between market price and analyst targets could indicate that analysts are behind the curve on negative company or industry developments.